Department of Emergency Medicine, University of New Mexico, MSC11 6025, 1 UNM, Albuquerque, NM, 87131-0001, USA.
Department of Emergency and Critical Care Medicine, Tokyo Bay Urayasu Ichikawa Medical Center, 3-4-32 Todaijima, Urayasu, Chiba, 279-0001, Japan.
J Anesth. 2019 Apr;33(2):238-249. doi: 10.1007/s00540-018-02606-0. Epub 2019 Jan 7.
Procedural sedation and analgesia (PSA) is widely performed outside of the operating theater, often in emergency departments (EDs). The practice and safety of PSA in the ED in an aging society such as in Japan have not been well described. We aimed to characterize the practice pattern of PSA including indications, pharmacology and incidence of adverse events (AEs) in Japan.
We formed the Japanese Procedural Sedation and Analgesia Registry, a multicenter prospective observation registry of ED patients undergoing PSA. We included all patients who received PSA in the ED. PSA was defined as any systemic pharmacological intervention intended to facilitate a painful or uncomfortable procedure. The main variables in this study were patients' demographics, American Society of Anesthesiologists (ASA) physical status, indication of PSA, medication choices, and AEs. The primary outcome measure was overall AEs from PSA.
We enrolled 332 patients in four EDs during the 12-month period. The median age was 67 years (IQR, 46-78). In terms of ASA physical status, 79 (23.8%), 172 (51.8%), and 81 (24.4%) patients were class 1, 2, 3 or higher, respectively. The most common indication was cardioversion (44.0%). The most common sedative used was thiopental (38.9%), followed by midazolam (34.0%) and propofol (19.6%). Among all patients, 72 (21.7%, 95% confidence interval, 17-26) patients experienced one or more AEs. The most common AE was hypoxia (9.9%), followed by apnea (7.2%) and hypotension (3.5%). All of the AEs were transient and no patient had a serious AE.
In a multicenter prospective registry in Japan, PSA in the ED appears safe particularly since the patients who underwent PSA were older and had a higher risk profile compared to patients in previous studies in different countries.
在手术室外,包括急诊科(ED)在内,经常会进行有创镇静和镇痛(PSA)。在老龄化社会(如日本)中,ED 中 PSA 的实施情况和安全性尚未得到充分描述。我们旨在描述日本 PSA 的实践模式,包括适应证、药理学和不良事件(AE)的发生率。
我们组建了日本有创镇静和镇痛登记处,这是一个 ED 接受 PSA 治疗的患者多中心前瞻性观察登记处。我们纳入了所有在 ED 接受 PSA 的患者。PSA 定义为任何旨在促进疼痛或不适操作的全身药理学干预。本研究的主要变量是患者的人口统计学、美国麻醉医师协会(ASA)身体状况、PSA 适应证、药物选择和 AE。主要结局指标是 PSA 引起的总体 AE。
在 12 个月期间,我们在 4 个 ED 共纳入了 332 名患者。中位数年龄为 67 岁(IQR,46-78)。就 ASA 身体状况而言,分别有 79(23.8%)、172(51.8%)和 81(24.4%)名患者为 1 级、2 级和 3 级或更高。最常见的适应证是电复律(44.0%)。最常用的镇静剂是硫喷妥钠(38.9%),其次是咪达唑仑(34.0%)和丙泊酚(19.6%)。在所有患者中,有 72 名(21.7%,95%置信区间,17-26)患者经历了 1 次或多次 AE。最常见的 AE 是缺氧(9.9%),其次是呼吸暂停(7.2%)和低血压(3.5%)。所有 AE 均为短暂性,无患者发生严重 AE。
在日本的多中心前瞻性登记处中,ED 中的 PSA 似乎是安全的,特别是与其他国家的先前研究相比,接受 PSA 的患者年龄更大,风险更高。